Confidential Informant assisted law enforcement in the investigation Written By: Leah Ward | ×
WINDOM A duo is set to appear in court Tuesday on criminal charges that they sold methamphetamine to a confidential informant (CI) working with the Cottonwood County Sheriff s Office.
The charges stem from several different drug sales that allegedly took place in September and October.
According to a criminal complaint filed April 6, on Sept. 3, 2020, a CI contacted CCSO and stated that they had arranged to purchase an eight ball (an eighth of an ounce, or 3.5 grams) of meth later that day from Mary Coleman, 39, of Windom. The CI was fitted with an audio recording device, and undercover officers had a visual on the CI during the exchange.
Disney+ Launchpad Trailer Showcases New Live-Action Short Films
comingsoon.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from comingsoon.net Daily Mail and Mail on Sunday newspapers.
In The Jungle, Singer Gene Jackson Brings Soul To His Longing For A Vaccine
stlpublicradio.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stlpublicradio.org Daily Mail and Mail on Sunday newspapers.
Published: Mar 11, 2021
New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation
TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021
RELEASE trial on track to report topline results in Q1 2021
Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021
Company to host conference call today at 8:30 a.m. ET
NEW HAVEN, Conn., March 11, 2021 (GLOBE NEWSWIRE) BioXcel, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its quarterly results for the fourth quarter and full year ended December 31, 2020